{"title":"Termitomyces mushroom extract-mediated synthesis of silver nanoparticles and its in-vitro activity against drug-resistant Candida species","authors":"Naheem Adekilekun Tijani , Joseph Hokello , Emmanuel Eilu , Saheed Adekunle Akinola , Abdullateef Opeyemi Afolabi , Ibrahim Ntulume , Ismail Abiola Adebayo","doi":"10.1016/j.crbiot.2025.100279","DOIUrl":null,"url":null,"abstract":"<div><div>Green nanotechnology has continued to gain popularity as a novel and alternative strategy to overcome the menace caused by drug-resistant pathogens. For the first time, this study explores an efficient, eco-friendly, and economical approach for the mycogenic synthesis of silver nanoparticles (AgNPs) by utilizing the aqueous extract of wild <em>Termitomyces</em> species of edible mushroom. The mushroom-assisted AgNPs synthesis was validated with visual colour observation and characterized with UV–Vis spectrophotometer, SEM, EDX, XRD, FTIR and DLS. The potential anticandidal efficacy of the synthesized AgNPs was investigated against six clinical isolates of resistant pathogenic <em>Candida</em> species. A typical Ag surface plasmon resonance (SPR) had absorbance maxima wavelength within 371–404 nm range, with a spherical shape particulate structure in the size range of 28 to 45 nm according to UV–Vis and SEM analyses respectively. Remarkable antifungal activity was recorded against a good number of the <em>Candida</em> isolates with MICs values in the range of 0.0122–0.0976 mg/mL. We conclude that wild <em>Termitomyces</em> mushroom is a suitable biomaterial for AgNPs synthesis and an effective antifungal agent which could be adopted as a novel therapeutic agent for efficient management of drug-resistant <em>Candida</em> pathogens.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100279"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262825000085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Green nanotechnology has continued to gain popularity as a novel and alternative strategy to overcome the menace caused by drug-resistant pathogens. For the first time, this study explores an efficient, eco-friendly, and economical approach for the mycogenic synthesis of silver nanoparticles (AgNPs) by utilizing the aqueous extract of wild Termitomyces species of edible mushroom. The mushroom-assisted AgNPs synthesis was validated with visual colour observation and characterized with UV–Vis spectrophotometer, SEM, EDX, XRD, FTIR and DLS. The potential anticandidal efficacy of the synthesized AgNPs was investigated against six clinical isolates of resistant pathogenic Candida species. A typical Ag surface plasmon resonance (SPR) had absorbance maxima wavelength within 371–404 nm range, with a spherical shape particulate structure in the size range of 28 to 45 nm according to UV–Vis and SEM analyses respectively. Remarkable antifungal activity was recorded against a good number of the Candida isolates with MICs values in the range of 0.0122–0.0976 mg/mL. We conclude that wild Termitomyces mushroom is a suitable biomaterial for AgNPs synthesis and an effective antifungal agent which could be adopted as a novel therapeutic agent for efficient management of drug-resistant Candida pathogens.
期刊介绍:
Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines.
Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.